B
Bull
Bull · 25%JBIO
$10.42
Precio del escenario
$21.020
-0.334 (-1.59%)Al cierre
Loading chart…
- High
- 21.615
- Open
- 21.320
- VWAP
- 21.12
- Vol
- 516.64K
- Mkt Cap
- —
- Low
- 20.730
- Amount
- 10.91M
- EV/EBITDA, TTM
- 0.00
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
AI analysis of Jade Biosciences Inc (JBIO)
buyJade Biosciences is a good buy right now due to its current price of $20.84, which is significantly below the average analyst price target of $45, indicating a potential upside of 116%. Additionally, the company has shown a strong year-to-date change of +47.18%, suggesting positive momentum. However, investors should be cautious of the high net loss of $55.76 million reported for Q2 2026, which reflects ongoing financial challenges.
Métricas de valoración
The current forward P/E ratio for Jade Biosciences Inc (JBIO) is 0.00, compared to its 5-year average forward P/E of -3.24.
Alphio AI Price Scenarios for JBIO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding JBIO
Cronología de eventos
Noticias
9.508-10NASDAQ.COMJade Biosciences Reports Wider Q2 Loss Amid Increased R&D Spending
5.006-26NewsfilterJade Biosciences Appoints New Board Member
8.506-24NASDAQ.COMBoundless Bio Merges with Serapha in All-Stock Deal
6.006-15CNBCLatest Wall Street Ratings Overview
8.506-04NASDAQ.COMJade Biosciences Prices Public Offering at $150 Million
JBIO FAQ — answered by Alphio AI
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development. It operates in the Healthcare sector.
Jade Biosciences is a good buy right now due to its current price of $20.84, which is significantly below the average analyst price target of $45, indicating a potential upside of 116%. Additionally, the company has shown a strong year-to-date change of +47.18%, suggesting positive momentum. However, investors should be cautious of the high net loss of $55.76 million reported for Q2 2026, which reflects ongoing financial challenges.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.